LIP
AUPH icon

Liontrust Investment Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Liontrust Investment Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-421,000
Closed -$4.08M – 193
2023
Q2 		$4.08M Sell
421,000
-25,500
-6% -$265K 0.06% 146
2023
Q1 		$4.89M Hold
446,500
– – 0.07% 141
2022
Q4 		$1.93M Hold
446,500
– – 0.03% 140
2022
Q3 		$3.36M Hold
446,500
– – 0.05% 160
2022
Q2 		$4.49M Hold
446,500
– – 0.06% 158
2022
Q1 		$5.53M Hold
446,500
– – 0.07% 115
2021
Q4 		$10.2M Buy
+446,500
New +$10.6M 0.12% 85

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Liontrust Investment Partners's AUPH Position: Q3 2023 in Review

Liontrust Investment Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2023, closing a stake of 421,000 shares — an estimated $4.08M sold.

Liontrust Investment Partners first reported a position in AUPH in Q4 2021 and held it in 7 quarters. The position peaked at $10.2M in Q4 2021. 198 funds tracked by Wall St. Rank hold AUPH as of Q3 2023.

  • Liontrust Investment Partners reported no remaining Aurinia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Liontrust Investment Partners sold 421,000 Aurinia Pharmaceuticals shares in Q3 2023, an estimated $4.08M.
  • Liontrust Investment Partners first reported a position in Aurinia Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • Liontrust Investment Partners's Aurinia Pharmaceuticals position peaked at $10.2M in Q4 2021.
  • 198 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2023.

Based on Liontrust Investment Partners's 13F filing for Q3 2023, filed 9 Nov 2023.